Gyrodyne (NASDAQ:GYRO) Stock Passes Below Two Hundred Day Moving Average – Should You Sell?

Gyrodyne , LLC (NASDAQ:GYROGet Free Report)’s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $6.77 and traded as low as $4.99. Gyrodyne shares last traded at $5.0590, with a volume of 13,130 shares changing hands.

Gyrodyne Trading Up 1.4%

The firm has a fifty day simple moving average of $5.50 and a two-hundred day simple moving average of $6.77.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Gyrodyne stock. Advisory Services Network LLC acquired a new position in Gyrodyne , LLC (NASDAQ:GYROFree Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 7,720 shares of the real estate investment trust’s stock, valued at approximately $77,000. Advisory Services Network LLC owned about 0.35% of Gyrodyne as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 71.36% of the company’s stock.

About Gyrodyne

(Get Free Report)

Gyrodyne Company of America, Inc is a New York–based real estate investment and development firm specializing in medical office buildings and professional facilities. Listed on the NASDAQ under the ticker GYRO, the company’s principal business activity is the ownership, leasing and management of commercial properties tailored to healthcare and life sciences tenants. By focusing on outpatient diagnostic and treatment centers, clinical laboratories and related professional suites, Gyrodyne generates steady rental income and seeks to provide purpose-built environments that meet the specific needs of medical practitioners and research organizations.

The company’s core property portfolio is anchored by an approximately 87-acre campus situated in Stony Brook, Long Island.

Featured Articles

Receive News & Ratings for Gyrodyne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyrodyne and related companies with MarketBeat.com's FREE daily email newsletter.